KoAct Biohealthcare Active, 11.1% Profit Rate in One Week

Samsung Active Asset Management announced on the 14th that the KoAct Biohealthcare Active Exchange-Traded Fund (ETF) exceeded an 11% return within just 7 trading days after its listing.

Samsung Active Asset Management's KoAct Biohealthcare Active is the only active ETF in Korea that invests in biohealthcare companies expected to experience high growth through the convergence of artificial intelligence (AI) technology. It constructs its portfolio by adding carefully selected stocks from Samsung Active Asset Management’s research based on the iSelect Biohealthcare PR Index.

The KoAct Biohealthcare Active ETF attracted market attention due to the distinctive features of its active management. Since its launch on the 3rd, both individual and institutional investors have poured funds into it, with net purchases approaching 50 billion KRW within just 6 days.

Furthermore, on the 11th, it recorded a return of 11.10% based on the closing price, ranking among the top performers out of 11 biohealthcare-related ETFs. Considering that the underlying index rose 7.95% during the same period, this means the active management’s advantage of proactive portfolio management generated an additional return of more than 3.15 percentage points (p), making the achievement even more meaningful.

As of August 14, 2023, the companies included in this ETF are ▲Celltrion Healthcare (7.71%), ▲Yuhan Corporation (7.60%), ▲Samsung Biologics (6.85%), ▲SK Biopharm (5.92%), and ▲Alteogen (4.89%). The portfolio also contains companies not included in the underlying index, such as Voronoi, FutureChem, and Wontech.

Seobeomjin, Head of Strategy Solutions at Samsung Active Asset Management, stated, "Recently, investments that were concentrated in secondary batteries have been diversifying into semiconductors, bio, and robotics. Investors who had been making large-scale purchases of secondary battery ETFs showed increased net purchases of bio ETFs on the 10th. While the KoAct Biohealthcare Active ETF is showing top-tier performance, it is important to note that the biohealthcare industry has been a long-neglected theme. Although investing based on this insight is good, a long-term investment approach considering sustainable growth is more desirable."

This content was produced with the assistance of AI translation services.